A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA

mAbs

Volumn 8, Issue 1, 2016, Pages 74-86

  Rouwendal, Gerard Johan A ^a   van der Lee, Miranda M ^a   Meyer, Saskia ^b   Reiding, Karli R ^c   Schouten, Jan ^a   de Roo, Guy ^a   Egging, David F ^a   Leusen, Jeanette H W ^b   Boross, Peter ^b   Wuhrer, Manfred ^c,d   Verheijden, Gijs F ^a   Dokter, Wim H ^a   Timmers, Marco ^a   Ubink, Ruud ^a  

^a SYNTHON BV   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Cysteine mutation; HER2; Monoclonal IgA antibody; N glycan sialylation; Pharmacokinetics; Transgenic FcaRI mouse model

Indexed keywords

ANTINEOPLASTIC AGENT; ASIALOGLYCOPROTEIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G1; TRASTUZUMAB; CANCER ANTIBODY; ERBB2 PROTEIN, HUMAN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; N ACETYLNEURAMINIC ACID; POLYSACCHARIDE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ARTICLE; BREAST CANCER; CELL PHAGOCYTOSIS; CELL PROLIFERATION; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NEUTROPHIL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; SIALYLATION; SIZE EXCLUSION CHROMATOGRAPHY; SURFACE PLASMON RESONANCE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VOLUME OF DISTRIBUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BREAST NEOPLASMS; COMPARATIVE STUDY; DRUG SCREENING; FEMALE; GLYCOSYLATION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; N-ACETYLNEURAMINIC ACID; POLYSACCHARIDES; RECEPTOR, ERBB-2; TRASTUZUMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964541182     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1102812     Document Type: Article

References (52)

1. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 1998; 95:652-6; PMID:9435247; http://dx.doi.org/10.1073/pnas.95.2.652
2. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704
3. Nimmerjahn F, Ravetch JV. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun 2012; 12:13; PMID:22896758
4. Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, et al. FcaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 1997; 90:4485-92; PMID:9373259
5. Huls G, Heijnen IAFM, Cuomo E, van der Linden J, Boel E, van de Winkel JGJ, Logtenberg T. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res 1999; 59:5778-84; PMID:10582699
6. Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, et al. Triggering Fcareceptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol 2000; 16:5954-61; http://dx.doi.org/10.4049/jimmunol.165.10.5954
7. Braster R, O'Toole T, van Egmond M. Myeloid cells as effector cells for monoclonal antibody therapy of cancer. Methods 2014; 65:28-37; PMID:23811299; http://dx.doi.org/10.1016/j.ymeth.2013.06.020
8. Otten MA, Bakema JE, Tuk CW, Glennie MJ, Tutt AL, Beelen RH, van de Winkel JGJ, van Egmond M. Enhanced FcaRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells. Eur J Immunol 2012; 42:1815-21; PMID:22535639; http://dx.doi.org/10.1002/eji.201141982
9. Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, van de Winkel JGJ, Valerius T. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 2007; 179:2936-43; PMID:17709508; http://dx.doi.org/10.4049/jimmunol.179.5.2936
10. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; PMID:11806974; http://dx. doi.org/10.1182/blood.V99.3.754
11. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-47; PMID:12975461; http://dx.doi.org/10.1200/JCO.2003.05.013
12. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neupositive metastatic breast cancer. J Clin Oncol 2008; 26:1789-96; PMID:18347005; http://dx.doi.org/10.1200/JCO.2007.14.8957
13. Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 2013; 5:1213-26; PMID:23918228; http://dx.doi.org/10.1002/emmm.201201929
14. van Egmond M, van Vuuren AJH, van de Winkel JGJ. The human Fc receptor for IgA (FcaRI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis. Immunol Lett 1999; 68:83-7; PMID:10397160; http://dx.doi.org/10.1016/S0165-2478(99)00034-6
15. Launay P, Grossetête B, Arcos-Fajardo M, Gaudin E, Torres SP, Beaudoin L, Patey-Mariaud de Serre N, Lehuen A, Monteiro RC. Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J Exp Med 2000; 191:1999-2009; PMID:10839814; http://dx.doi.org/10.1084/jem.191.11.1999
16. Soua Z, Ghanem N, Ben Salem M, Lefranc G, Lefranc MP. Frequencies of the human immunoglobulin IGHA2*M1 and IGHA2*M2 alleles corresponding to the A2m(1) and A2m(2) allotypes in the French, Lebanese, Tunisian and black African populations. Nucleic Acids Res 1989; 17:3625; PMID:2566982; http://dx. doi.org/10.1093/nar/17.9.3625
17. Toraño A, Tsuzukida Y, Liu YS, Putnam FW. Location and structural significance of the oligosaccharides in human IgA1 and IgA2 immunoglobulins. Proc Natl Acad Sci U S A 1977; 74:2301-5; http://dx.doi.org/10.1073/pnas.74.6.2301
18. Mattu TS, Pleass RJ, Willis AC, Kilian M, Wormald MR, Lellouch AC, Rudd PM, Woof JM, Dwek RA. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-Glycosylation on Fca receptor interactions. J Biol Chem 1998; 273:2260-72; PMID:9442070; http://dx.doi.org/10.1074/jbc.273.4.2260
19. Tsuzukida Y, Wang CC, Putnam FW. Structure of the A2m(1) allotype of human IgA - a recombinant molecule. Proc Natl Acad Sci U S A 1979; 76:1104-8; PMID:286295; http://dx.doi.org/10.1073/pnas.76.3.1104
20. Zhang N, Liu L, Dumitru CD, Cummings NR, Cukan M, Jiang Y, Li Y, Li F, Mitchell T, Mallem MR, et al. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. mAbs 2011; 3:289-98; PMID:21487242; http://dx.doi.org/10.4161/mabs.3.3.15532
21. Beyer T, Lohse S, Berger S, Peipp M, Valerius T, Dechant M. Serum-free production and purification of chimeric IgA antibodies. J Immunol Methods 2009; 346:26-37; PMID:19427867; http://dx.doi.org/10.1016/j.jim.2009.05.002
22. Yoo EM, Coloma MJ, Trinh KR, Nguyen TQ, Vuong LU, Morrison SL, Chintalacharuvu KR. Structural requirements for polymeric immunoglobulin assembly and association with J chain. J Biol Chem 1999; 274:33771-7; PMID:10559270; http://dx.doi.org/10.1074/jbc.274.47.33771
23. Brunke C, Lohse S, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, Royle L, Liew LP, et al. Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody. MAbs 2013; 5:936-45; PMID:24492345; http://dx.doi.org/10.4161/mabs.26396
24. Chintalacharuvu KR, Yu LJ, Bhola N, Kobayashi K, Fernandez CZ, Morrison SL. Cysteine residues required for the attachment of the light chain in human IgA2. J Immunol 2002; 169:5072-7; PMID:12391223; http://dx.doi.org/10.4049/jimmunol.169.9.5072
25. Chintalacharuvu KR, Gurbaxani B, Morrison SL. Incomplete assembly of IgA2m(2) in Chinese hamster ovary cells. Mol Immunol 2007; 44:3445-52; PMID:17467056; http://dx.doi.org/10.1016/j. molimm.2006.12.030
26. Fallgren-Gebauer E, Gebauer W, Bastian A, Kratzin HD, Eiffert H, Zimmermann B, Karas M, Hilschmann N. The covalent linkage of secretory component to IgA. Structure of sIgA. Biol Chem Hoppe Seyler 1993; 374:1023-8; http://dx.doi.org/10.1515/bchm3. 1993.374.7-12.1023
27. Smith RI, Morrison SL. Recombinant polymeric IgG: an approach to engineering more potent antibodies. Biotechnology (N Y) 1994; 12:683-8; PMID:7764912; http://dx.doi.org/10.1038/nbt0794-683
28. Sørensen V, Rasmussen IB, Sundvold V, Michaelsen TE, Sandlie I. Structural requirements for incorporation of J chain into human IgM and IgA. Int Immunol 2000; 12:19-27; PMID:10607746; http://dx.doi. org/10.1093/intimm/12.1.19
29. Rifai A, Fadden K, Morrison SL, Chintalacharuvu KR. The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)a1 and Iga2 isotypes. J Exp Med 2000; 191:2171-81; PMID:10859341; http://dx.doi.org/10.1084/jem.191.12.2171
30. Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 2006; 18:1759-69; PMID:17077181; http://dx.doi.org/10.1093/intimm/dxl110
31. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970; 49:673-80; PMID:5443170; http://dx.doi.org/10.1172/JCI106279
32. Blaese RM, Strober W, Levy AL, Waldmann TA. Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism. J Clin Invest 1971; 50:2331-8; PMID:5096517; http://dx.doi.org/10.1172/JCI106731
33. Delacroix DL, Elkom KB, Geubel AP, Hodgson HF, Dive C, Vaerman JP. Changes in size, subclass, and metabolic properties of serum immunoglobulin A in liver diseases and in other diseases with high serum immunoglobulin A. J Clin Invest 1983; 71:358-67; PMID:6401770; http://dx.doi.org/10.1172/JCI110777
34. Moldoveanu Z, Epps JM, Thorpe SR, Mestecky J. The sites of catabolism of murine monomeric IgA. J Immunol 1988; 141:208-13; PMID:2454258
35. Weikert S, Papac D, Briggs J, Cowfer D, Tom S, Gawlitzek M, Lofgren J, Mehta S, Chisholm V, Modi N, et al. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat Biotechnol 1999; 17:1116-21; PMID:10545921; http://dx.doi.org/10.1038/15104
36. Park EI, Mi Y, Unverzagt C, Gabius HJ, Baenziger JU. The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acid a 2,6GalNAc. Proc Natl Acad Sci U S A 2005; 102:17125-9PMID:16286643; http://dx.doi.org/10.1073/pnas.0508537102
37. Steirer LM, Park EI, Townsend RR, Baenziger JU. The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid a2,6-galactose. J Biol Chem 2009; 284:3777-83; PMID:19075021; http://dx.doi.org/10.1074/jbc. M808689200
38. Reiding KR, Blank D, Kuijper DM, Deelder AM, Wuhrer M. High-throughput profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-specific sialic acid esterification. Anal Chem 2014; 86:5784-93; PMID:24831253; http://dx.doi.org/10.1021/ac500335t
39. Kitagawa H, Paulson JC. Cloning of a novel a 2,3-sialyltransferase that sialylates glycoprotein and glycolipid carbohydrate groups. J Biol Chem 1994; 269:1394-1401; PMID:8288606
40. x trisaccharide and related glycan ligands. J Biol Chem 2005; 280:22993-9; PMID:15845541; http://dx.doi.org/10.1074/jbc.M504197200
41. X-containing ligands cleared by the scavenger receptor C-type lectin. J Biol Chem 2011; 286:24336-49; PMID:21561871; http://dx.doi.org/10.1074/jbc. M111.244772
42. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011; 21:949-59; PMID:21421994; http://dx.doi.org/10.1093/glycob/cwr027
43. Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JH, Bleeker WK, Parren PW. Crosstalk between human IgG isotypes and murine effector cells. J Immunol 2012; 189:3430-8; PMID:22956577; http://dx.doi.org/10.4049/jimmunol.1200356
44. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, et al. Existent T-cell and antibody immunity to HER2/neu protein in patients with breast cancer. Cancer Res 1994; 54:16-20; PMID:7505195
45. Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007; 13:5133-43; PMID:17785568; http://dx.doi.org/10.1158/1078-0432.CCR-07-0507
46. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013; 19:1858-72; PMID:23444227; http://dx.doi.org/10.1158/1078-0432.CCR-12-2426
47. Shen L, van Egmond M, Siemasko K, Gao H, Wade T, Lang ML, Clark M, van De Winkel JGJ, Wade WF. Presentation of ovalbumin internalized via the immunoglobulin-A Fc receptor is enhanced through Fc receptor g-chain signaling. Blood 2001; 97:205-13; PMID:11133762; http://dx.doi.org/10.1182/blood. V97.1.205
48. Lang ML, Shen L, Gao H, Cusack WF, Lang GA, Wade WF. Fca receptor cross-linking causes translocation of phosphatidylinositol-dependent protein kinase 1 and protein kinase Ba to MHC Class II peptideloading-like compartments. J Immunol 2001; 166:5585-93; PMID:11313398; http://dx.doi.org/10.4049/jimmunol.166.9.5585
49. Otten MA, Groenveld I, van de Winkel JGJ, van Egmond M. Inefficient antigen presentation via the IgA Fc receptor (FcaRI) on dendritic cells. Immunobiology 2006; 211:503-10; PMID:16920489; http://dx. doi.org/10.1016/j.imbio.2006.05.016
50. Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, Dall'Acqua WF, Tsui P. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcaRI (CD89) binding. MAbs 2015; 7(4):743-51
51. Selman MHJ, Hemayatkar M, Deelder AM, Wuhrer M. Cotton HILIC SPE microtips for microscale purification and enrichment of glycans and glycopeptides. Anal Chem 2011; 83:2492-9; PMID:21366235; http://dx.doi.org/10.1021/ac1027116
52. Ceroni A, Maass K, Geyer H, Geyer R, Dell A, Haslam SM. GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. J Proteome Res 2008; 7:1650-9; PMID:18311910; http://dx.doi.org/10.1021/pr7008252